

Anaesthetic Strategy During Endovascular Therapy:

General Anaesthesia or Conscious Sedation ?

(“GOLIATH” – General Or Local anaesthesia in Intra Arterial THERapy”)

Claus Z. Simonsen, Leif Sørensen, Niels Juul, Alp Tankisi, Bent Dahl, Anne-Marie Jensen, Stig Dyrskog, Morten H. Kirk, Klaus U. Koch, Marianne Rhode, Lisbeth Krogh, Christian Fenger, Knud Goldbækdahl, Sanja Karabegovic, Grethe Andersen, Mads Rasmussen

The Danish Stroke Centre and Departments of Neurology, Anaesthesia and Neuroradiology, Aarhus University Hospital, Aarhus, Denmark

Ischemic stroke is the third leading cause of death and the most common cause of acquired disability among adults in the western world. The only evidence-based therapy in acute ischemic stroke (AIS) is intra-venous (IV) tissue-plasminogen activator (tPA) also called thrombolysis (1). However, in patients with large artery stroke 50–70 % of all patients fail treatment with IV tPA due to recanalization failure (2). Removing the arterial occlusion has proven to be the best predictor of outcome. In addition, there is a significant proportion of patients in whom IV tPA is contraindicated. Under these circumstances endovascular therapy (EVT) with mechanical or pharmacological clot removal is the only treatment option.

Controversy exists whether general anaesthesia (GA) or conscious sedation (CS) should be used during EVT for acute ischemic stroke (AIS) (3,4). Currently there are no high quality randomised prospective trials addressing this question. Benefits of GA include airway protection, pain control and patient immobility for motion-free radiographic imaging and intervention. Conversely, GA is time consuming and possibly associated with longer time to revascularization and periods of hypotension with the risk of further ischemic injury (5,6). Advantages of CS might include shorter time to revascularization, fewer hemodynamic problems, the possibility for better neurological assessment during the procedure and possibly a faster procedure. The main arguments against CS are that patient movement can result in procedural complications, lack of airway control, higher

28 radiation dose and the need of more contrast media (5,6).

29 Recent retrospective studies have suggested that GA may worsen neurological outcome
30 and increase mortality (7-11). However, National Institute of Health Stroke Score (NIHSS)
31 was higher in the GA group, and GA was reserved for patients who could not cooperate
32 and those with airway obstruction. None of the studies included a specific description of
33 the criteria for selecting either GA or CS. Furthermore, systolic blood pressure below 140
34 mmHg appears to be related to worse outcome (9), but none of the retrospective studies
35 present detailed blood pressure data. Thus, the level of evidence is low and to address
36 this problem, patients subjected to EVT will be randomized to either GA or CS and their
37 outcome will be followed.

38 As a standard procedure, Magnetic Resonance Imaging (MRI) will be performed before
39 and after EVT. Outcome with respect to choice of anaesthetic regime is determined by
40 changes in the modified Rankin scale (mRS) and infarct growth judged by MRI.

41

42 **Hypothesis**

43 We hypothesize that patients receiving endovascular therapy under CS is associated with
44 a better outcome, i.e. lower mRS and infarct size after EVT.

45 **Aim of the study**

46 The main objective is to determine whether the use of GA or CS during endovascular clot
47 removal in AIS patients influence patient outcome. Specifically, we will determine whether
48 there is a difference in the primary and secondary outcome measures mentioned below.

49 The two groups will be compared in regards to:

50 Primary outcome measures

51 1. Growth of DWI lesion (infarct) on 48-72 hour follow up MRI (for all and for anterior
52 strokes only).

53 2. Modified Rankin Score after 90 days

54

55 Secondary outcome measures

56 1. Time parameters

- 57 a. Time from arrival at angiography suite to groin puncture
- 58 b. Time from groin puncture to recanalization or end of procedure
- 59 c. Time from arrival at angiography suite to recanalization or end of procedure
- 60 d. Time from symptom onset to recanalization or end of procedure

61 2. Blood pressure variables:

- 62 a. 20% drop in Mean Arterial Blood pressure (MABP) (relative to pre-induction MABP)
- 63 during procedure
- 64 b. MABP < 90 mmHg
- 65 c. MABP < 70 mmHg
- 66 d. Minutes with MABP < 70 mmhg
- 67 e. Lowest and highest MABP during procedure
- 68 f. Post-reperfusion MABP (measured immediately after reperfusion is obtained)
- 69 g. Post procedure MABP (measured in recovery room)

70 3. Use of vasopressors (ephedrine/phenylephrine)

71 4. Complications

- 72 a. Target vessel lesion (rupture, dissection)
- 73 b. Access vessel dissection
- 74 c. Clot migration to another, unaffected vascular territory

75 5. Other

- 76 a. 24 hour NIHSS change
- 77 b. Successful recanalization (mTICI 2b-3)
- 78 c. Total radiation dose (DAB)
- 79 d. Total amount of contrast media (ml)

80

81 In addition to the primary and secondary outcome measures we intend to register
82 anesthetic complications related to conscious sedation and general anesthesia. This
83 include: patient agitation/discomfort, need to convert to general anesthesia and airway
84 management problems.

85

86 **Material and methods**

87 Patients with ischemic stroke scheduled for acute EVT will be included in the study.

88 ***Inclusion criteria:***

- 89 1) Severe stroke (NIHSS \geq 10)
- 90 2) mRS \leq 2 before stroke
- 91 3) Groin puncture (arterial cannulation) feasible within 6 hours of symptom onset
- 92 4) MRI findings
 - 93 a. Clot in a reachable vessel. (ICA, ICA-T, M1, M2)
 - 94 b. Infarct volume <70ml on the initial scan

95 ***Exclusion criteria***

- 96 1) MRI contraindications
- 97 2) GCS < 9
- 98 3) Patients intubated prior to arrival
- 99 4) Previous allergic reactions to anesthetics

100 ***Anaesthesia protocol:***

101 *General anaesthesia:* Rapid sequence intubation (Suxamethonium/alfentanil/propofol).

102 Tracheal intubation and mechanical ventilation. Anaesthesia is maintained with propofol
103 and remifentanil according to institutional guidelines

104 *Conscious Sedation:* The overall goal is to reduce agitation, anxiety, movements and still
105 be able to communicate with the patient

- 106 1. Fentanyl bolus 25-50 ug. This dose may be repeated.

107 2. Propofol infusion. 1-2 mg/kg/h. If deemed necessary by the
108 anesthesiologist the infusion rate can be increased or reduced

109

110 Monitoring:

111 Electrocardiography, pulseoximetry, end-tidal carbon dioxide and continuous invasive
112 blood pressure measurements are performed during the procedure. The general goal is to
113 maintain MABP \geq 70 mmHg during the procedure (11). A reduction in MABP ($<$ 70 mmHg)
114 $>$ 30 seconds is treated with vasopressors (ephedrine/phenylephrine)

115 **Data collection during the study:**

116 Demographical data: Age, gender, hypertension, diabetes mellitus, smoking, ischemic
117 heart disease, known congestive heart failure, atrial fibrillation.

118 Stroke data: NIHSS, clot location (ICA, ICA-T, M1, M2), side (left, right). Infarct size before
119 procedure (DWI), size of perfusion lesion (PWI), microbleeds, leucoaraiosis (Fazeka
120 Scale) , recanalization (modified TICl score), infarct size after 24 hours, hemorrhagic
121 transformation (HI-1, HI-2, PH-1, PH-2), 24 hour NIHSS, 90 day mRS.

122 Time-related data: Symptom onset/last seen well, time of admission, time of MRI scan,
123 time to thrombolysis, time to arrival at angio-suite, time to groin puncture, time to
124 recanalization, time to end of procedure.

125 Data measured during procedure: The need to convert to GA from CS (airway, agitation).
126 Continuous invasive blood pressure. Blood pressure data are sampled continuously and
127 stored on a laptop. The use of vasopressors (ephedrine/phenylephrine) will be recorded.

128

129 **Data analysis and statistics**

130 A power analysis showed that a sample size of $n = 128$ would be required in order to
131 detect a 10 ml mean difference (SD 20 ml, alpha 0.05 and power of 0.8) in the volume of
132 infarcted tissue between the GA and the LA group, respectively. We estimate it will take
133 about 2 years to accomplish enrollment.

134 All data are entered into a database. Statistical analysis will be performed where we will
135 compare the primary and secondary outcomes in the GA and LA groups.

136

137 **Ethics and consent**

138 *Why should this study be conducted as an "Acute Study"*

139 The patients all suffer from a large ischemic stroke, which often involve a major part of the
140 brain. Aphasia is a typical symptom at admission, which means that they are unable to
141 speak and very often unable to understand any given information. If the right hemisphere
142 is affected, the patients often present with severe neglect/anosognosia, meaning that they
143 have no insight in their situation being in a state of disbelief and indifference to their
144 symptoms. If the ischemic stroke involves the large arteries in the posterior part of the
145 brain, the patients may have decreased consciousness and often appear in a comatose
146 condition. Thus, the patients are unable to make crucial decisions.

147 Furthermore, the treatment has to be initiated very quickly. It is estimated that patients are
148 losing 1.9 million brain cells per minute during a large vessel occlusion in the brain. The
149 likelihood of a good outcome decreases with 10% every 30 minutes that passes.

150 Since the majority of the patients are incapacitated at admission and since the treatment is
151 severely time dependent, we found that the conditions for an acute study are fulfilled.

152 Consent

153 We will randomize to GA or CS without consent. Since there are no national or
154 international guidelines as to whether GA or CS should be offered in this situation and
155 since the focus of the study is to test two different anaesthesia procedures and not drugs,
156 we do not find it necessary to obtain consent from patient or relative prior to EVT. The
157 patients and their relatives will be informed that the patient will be offered EVT, which is
158 our standard procedure.

159 After the procedure, the patient will be presented with a consent form with information
160 about the study. We will ask for his acceptance to be in the study. The only thing that will
161 differ for the patient being in the study, is the extra MRI scan to be performed 48-72 hours
162 after the procedure. All other scans, tests and the follow-up are parts of our usual routine.
163 The patient can withdraw consent anytime.

164 If the patient is in a state, where we cannot obtain consent, consent will be obtained from
165 next of kin.

166

167 **Perspective**

168 This randomized, prospective study will provide important data on whether outcome is
169 influenced by the anesthetic technique during EVT. This knowledge may have great
170 impact on the future choice of anesthetic technique during EVT of large vessel stroke.

171

172 **Dansk resume:**

173 Blodprop i hjernen er en alvorlig sygdom, hvor der er stor risiko for død og/eller handicap.
174 Den nuværende og eneste behandling med dokumenteret positiv effekt er trombolyse,
175 hvor man indsprøjter kraftigt blodfortyndende medicin. Hvis der er tale om en stor blodprop
176 er dette ofte ikke nok. I disse tilfælde kan man fjerne blodproppen med et kateter i den
177 lukkede pulsåre. Dette kaldes Endovaskulær Terapi (EVT). Dette har dog ikke vist sig at
178 være bedre end medicinsk behandling i randomiserede undersøgelser.

179 I dette studie vil vi randomisere patienter, som vi ellers alligevel vil tilbyde EVT, til enten
180 EVT under fuld bedøvelse (general anæstesi) eller under sedation, hvor patienten ligger
181 og døser, men kan vækkes. Begge former for bedøvelse vil blive styret af anæstesiologer
182 med særlig neuroanæstesiologisk kompetence

183 Vi vil opsamle data, der omfatter blodtryk, tidspunkt for de forskellige
184 behandlingsmomenter, grad af handicap efter behandling samt volumen af skadet
185 hjernevæv vurderet på MR scanning. Alle disse parametre registrerer vi i forvejen. Vi vil
186 sammenligne det endelige omfang af skadet væv i hjernen hos patienter, der blev
187 behandlet med de to forskellige bedøvelsesmetoder for at belyse om bedøvelsesmetoden
188 påvirker behandlingsresultatet.

189

190

191

192

193

194

195

196

197

198 **References**

199

200 1: NINDS rt-PA Stroke Study Group (1995) Tissue plasminogen activator for acute
201 ischemic stroke. *N Engl J Med* 333:1581–1587

202 2: Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-
203 analysis. *Stroke* 2007;38: 967–973.

204 3: Brekenfeld C, Mattle HP, Schroth G. General is better than local anesthesia
205 during endovascular procedures. *Stroke*. 2010 Nov;41(11):2716-7.

206 4: Gupta R. Local is better than general anesthesia during endovascular acute
207 stroke interventions. *Stroke*. 2010 Nov;41(11):2718-9.

208 5: Froehler MT, Fifi JT, Majid A, Bhatt A, Ouyang M, McDonagh DL. Anesthesia for
209 endovascular treatment of acute ischemic stroke. *Neurology*. 2012 Sep 25;79(13
210 Suppl 1):S167-73. Review.

211 6: John N, Mitchell P, Dowling R, Yan B. Is general anaesthesia preferable to
212 conscious sedation in the treatment of acute ischaemic stroke with intra-arterial
213 mechanical thrombectomy? A review of the literature. *Neuroradiology*. 2013
214 Jan;55(1):93-100.

215 7: Abou-Chebl A, Lin R, Hussain MS, Jovin TG, Levy EI, Liebeskind DS, Yoo AJ, Hsu
216 DP, Rymer MM, Tayal AH, Zaidat OO, Natarajan SK, Nogueira RG, Nanda A, Tian M,
217 Hao Q, Kalia JS, Nguyen TN, Chen M, Gupta R. Conscious sedation versus general
218 anesthesia during endovascular therapy for acute anterior circulation stroke:
219 preliminary results from a retrospective, multicenter study. *Stroke*. 2010
220 Jun;41(6):1175-9.

221 8: Jumaa MA, Zhang F, Ruiz-Ares G, Gelzini T, Malik AM, Aleu A, Oakley JI,
222 Jankowitz B, Lin R, Reddy V, Zaidi SF, Hammer MD, Wechsler LR, Horowitz M, Jovin
223 TG. Comparison of safety and clinical and radiographic outcomes in endovascular
224 acute stroke therapy for proximal middle cerebral artery occlusion with
225 intubation and general anesthesia versus the nonintubated state. *Stroke*. 2010

226 Jun;41(6):1180-4.

227 9: Davis MJ, Menon BK, Baghirzada LB, Campos-Herrera CR, Goyal M, Hill MD, Archer
228 DP; Calgary Stroke Program. Anesthetic management and outcome in patients during
229 endovascular therapy for acute stroke. *Anesthesiology*. 2012 Feb;116(2):396-405.

230 10: Li F, Deshaies EM, Singla A, Villwock MR, Melnyk V, Gorji R, Yang ZJ. Impact
231 of anesthesia on mortality during endovascular clot removal for acute ischemic
232 stroke. *J Neurosurg Anesthesiol*. 2014 Oct;26(4):286-90.

233

234 11: Whalin MK, Lopian S, Wyatt K, Sun CH, Nogueira RG, Glenn BA, Gershon RY, Gupta
235 R. Dexmedetomidine: a safe alternative to general anesthesia for endovascular
236 stroke treatment. *J Neurointerv Surg*. 2014 May;6(4):270-5.

237

238 Statistical Analysis Plan:

239 Statistical analyses

240 The primary analysis will be performed unadjusted and according to the intention-to-treat
241 principle. This means that a cross-over patient from CS to GA will stay in the CS group for
242 analysis. Data will be analyzed using conventional appropriate test statistics stratified
243 according to NIHSS and age depending on the distribution of the individual outcome
244 parameters (including paired t-test or Wilcoxon signed rank test for infarct volume and
245 Mann–Whitney for mRS).

246 Supplementary analyses using multivariable regression will be done in order to account for
247 any imbalances in the distribution of prognostic factors between the two treatment arms. A
248 generalized linear mixed model will be used for comparing infarct growth in the two
249 treatment arms. Ordinal and logistic regression will be used for comparing 90 days mRS.
250 Univariate ($p < 0.10$) predictors of infarct growth and 90 days mRS, respectively, will be
251 included in the supplementary multivariable analyses. The association between MABP and
252 mRS will be examined using multivariable polynomial regression.

253 Statistical significance is defined as a two-tailed $p < 0.05$.